Cargando…

Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

INTRODUCTION: Multiple myeloma (MM) is an extremely malignant and incurable hematological cancer. Increased expression of the c-Myc oncoprotein is closely associated with shorter overall survival of MM patients, implying that c-Myc is a potential therapeutic target. MAIN METHODS: We identified a pot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Ruosi, Xie, Yu, Sun, Xiaoyang, Zhang, Menghui, Zhou, Jian, Liu, Linlin, Gao, Jian, Xu, Kailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532311/ https://www.ncbi.nlm.nih.gov/pubmed/33061303 http://dx.doi.org/10.2147/DDDT.S264077

Ejemplares similares

Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
por: Yao, Ruosi, et al.
Publicado: (2022)

Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells
por: Yao, Ruosi, et al.
Publicado: (2018)

Identification of Potential Prognostic Biomarker for Predicting Survival in Multiple Myeloma Using Bioinformatics Analysis and Experiments
por: Zhou, Jian, et al.
Publicado: (2021)

EHMTI-0037. Botulinum A toxin for treatment of chronic migraine
por: Grazzi, L, et al.
Publicado: (2014)

Anti-Proliferative Activity of HPOB against Multiple Myeloma Cells via p21 Transcriptional Activation
por: Liu, Linlin, et al.
Publicado: (2018)

The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
por: Sun, Xiaoyang, et al.
Publicado: (2019)

Cap0037, a Novel Global Regulator of Clostridium acetobutylicum Metabolism
por: Nguyen, Ngoc-Phuong-Thao, et al.
Publicado: (2016)

MYC inhibitors in multiple myeloma
por: Martínez-Martín, Sandra, et al.
Publicado: (2021)

Genome Sequence of the Tropical Atmosphere Bacterium Pontibacter sp. Strain SGAir0037
por: Lim, Serene B. Y., et al.
Publicado: (2019)

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers
por: Prothon, Susanne, et al.
Publicado: (2019)

Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers
por: Prothon, Susanne, et al.
Publicado: (2022)

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2015)

Stimulant Reduction Intervention using Dosed Exercise (STRIDE) - CTN 0037: Study protocol for a randomized controlled trial
por: Trivedi, Madhukar H, et al.
Publicado: (2011)

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2018)

Biophysical and Biochemical Characterization of TP0037, a d-Lactate Dehydrogenase, Supports an Acetogenic Energy Conservation Pathway in Treponema pallidum
por: Deka, Ranjit K., et al.
Publicado: (2020)

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

Anaplastic multiple myeloma with MYC rearrangement
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib
por: Cao, Yang, et al.
Publicado: (2021)

Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma
por: Liu, Linlin, et al.
Publicado: (2018)

Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells
por: Yao, Yao, et al.
Publicado: (2016)

Novel Mycosin Protease MycP(1) Inhibitors Identified by Virtual Screening and 4D Fingerprints
por: Hamza, Adel, et al.
Publicado: (2014)

Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4‐MYC oncogenic axis in multiple myeloma
por: Agnarelli, Alessandro, et al.
Publicado: (2022)

Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma
por: Affer, Maurizio, et al.
Publicado: (2014)

TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma
por: Håland, Erling, et al.
Publicado: (2022)

Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial
por: Brown, Mary N., et al.
Publicado: (2019)

Oncogene addiction to c-MYC in myeloma cells
por: Holien, Toril, et al.
Publicado: (2012)

Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation
por: Effenberger, Madlen, et al.
Publicado: (2017)

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2020)

Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
por: Ortiz-Ruiz, Alejandra, et al.
Publicado: (2021)

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA
por: Hasan Bou Issa, L., et al.
Publicado: (2022)

Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase
por: Dorasamy, Mathura Subangari, et al.
Publicado: (2017)

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma
por: Matthews, G M, et al.
Publicado: (2013)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma
por: Sharma, Neeraj, et al.
Publicado: (2021)

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma
por: Faruq, Omar, et al.
Publicado: (2022)

IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
por: Pisano, Michael D., et al.
Publicado: (2023)

Identification of a novel SPT inhibitor WXP-003 by docking-based virtual screening and investigation of its anti-fungi effect
por: Wang, Xin, et al.
Publicado: (2021)

Virtual screening and experimental validation of novel histone deacetylase inhibitors
por: Huang, Yan-xin, et al.
Publicado: (2016)

A Novel Inhibitor of Human La Protein with Anti-HBV Activity Discovered by Structure-Based Virtual Screening and In Vitro Evaluation
por: Tang, Jing, et al.
Publicado: (2012)

Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma
por: Luo, Yanwei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rbcst06113ku8mn2euhng5qv6n